Skip to main content

Proteome Sciences, ProQinase Start Biomarker Project

NEW YORK (GenomeWeb News) – Proteome Sciences, ProQinase, and the NMI Natural and Medical Sciences Institute at the University of Tübingen have started a three-year project to establish new workflows for developing and evaluating inhibitors targeting tumor protein kinases, Proteome Sciences said today.

The aim of the BioTag project, which is funded by the German Federal Ministry of Research and NMI, is to develop biomarker tests that can support kinase target validation studies, establish proof of concept for candidate kinase inhibitors, and to monitor treatment response in pre-clinical and early clinical studies.

The project will develop new molecular strategies for target expression and biomarker profiling and develop biomarkers that will be used to translate early drug candidates into human clinical trials.

"The need for more objective measures of drug safety and efficacy during pre-clinical and clinical development is widely recognized and the adoption of biomarkers for such purposes is supported by the pharmaceutical industry and regulators," Proteome Sciences CEO Christopher Pearce said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.